Barrett's Esophagus & Gastroesophageal Reflux Disease

NCT ID: NCT00513331

Last Updated: 2014-01-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study of Barrett's Esophagus (BE) and Gastroesophageal Reflux Disease (GERD). It aims to look at the long term efficacy of evidence-based cutting edge diagnostic and therapeutic algorithms and techniques such as radiofrequency ablation, endoscopic mucosal resection and surveillance endoscopy with biopsy. Additionally, biological analyses will be performed in hopes of identifying biomarkers associated with the progression of BE to esophageal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Barrett's esophagus (BE) is a known premalignant condition of the esophagus, predisposing to the development of esophageal adenocarcinoma. BE represents a change in the lining (mucosa) of the esophagus which is known to be produced as a result of chronic gastroesophageal reflux. The current standard of care for patients with BE includes serial performance of upper endoscopy with multiple biopsies, performed at designated time intervals. However, the emergence of new technologies for the management of this condition has made the care of these patients non-uniform, and subject to biases of individual treating physicians.

The protocol at The Valley Hospital and Blumenthal Cancer Center aims to standardize the management of patients with Barrett's esophagus, with and without dysplasia, using evidence-based, cutting edge diagnostic and therapeutic algorithms and techniques such as radiofrequency ablation, endoscopic mucosal resection, and surveillance endoscopy with biopsies. If biopsies suggest the development of carcinoma or high grade dysplasia surgical removal of the esophagus is recommended. This study aims to look at the long-term efficacy of these procedures. In addition, data regarding clinical outcomes will be collected as well as blood, tissue and surgical specimens for proteomic analysis in hopes of identifying biomarkers associated with the progression of dysplasia to adenocarcinoma. Although patients will ultimately make their own informed decisions regarding the management of their BE, this protocol serves to unify physician recommendations, and allows for the collection and interpretation of data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Barrett's Esophagus GERD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Algorithm #1

Patients without visable lesions

Endoscopy

Intervention Type PROCEDURE

Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.

Algorithm #2

Patients with a visable lesion that is less than 1cm

Endoscopy

Intervention Type PROCEDURE

Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.

Radiofrequency ablation protocol

Intervention Type PROCEDURE

Ablation using the HALO 360 system according to protocol established by BARRX, Inc.

Endoscopic mucosal resection protocol

Intervention Type PROCEDURE

Excision of lesion using DUETTE, marketed by Wilson-Cook

Algorithm #3

Patients with a visable lesion greater than 1cm

Endoscopy

Intervention Type PROCEDURE

Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.

Radiofrequency ablation protocol

Intervention Type PROCEDURE

Ablation using the HALO 360 system according to protocol established by BARRX, Inc.

Endoscopic mucosal resection protocol

Intervention Type PROCEDURE

Excision of lesion using DUETTE, marketed by Wilson-Cook

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopy

Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.

Intervention Type PROCEDURE

Radiofrequency ablation protocol

Ablation using the HALO 360 system according to protocol established by BARRX, Inc.

Intervention Type PROCEDURE

Endoscopic mucosal resection protocol

Excision of lesion using DUETTE, marketed by Wilson-Cook

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, age 18 to 85.
* Patient must have Barrett's Esophagus. Patients may be enrolled based on previous endoscopy reports and/or pathology reports. It is not necessary that each patient have endoscopy for the sole purpose of enrollment.
* Must agree to allow their clinical information to be collected, stored, analyzed and reported.
* Must allow portions of their biopsy/surgical specimens to be collected, stored, analyzed and reported.
* Must agree to fill out patient questionnaires in conjunction with the research study assistant assigned to this protocol (either in person or via telephone contact) at designated timepoints.

Exclusion Criteria

* Intestinal metaplasia of the cardia, without an esophageal columnar lining.
* Unable to provide informed consent.
* Unable or unwilling to undergo endoscopic procedures.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Valley Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert J. Korst, MD

Role: PRINCIPAL_INVESTIGATOR

Valley Health Systems/ The Valley Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Valley Health System - The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VHS07.0017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Epithelial Damage in GERD
NCT01867931 COMPLETED